» Articles » PMID: 24739903

Somatic Mutation of GRIN2A in Malignant Melanoma Results in Loss of Tumor Suppressor Activity Via Aberrant NMDAR Complex Formation

Overview
Publisher Elsevier
Specialty Dermatology
Date 2014 Apr 18
PMID 24739903
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The ionotropic glutamate receptors (N-methyl-D-aspartate receptors (NMDARs)) are composed of large complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx or efflux of mono- or divalent cations (e.g., Ca(2+)) important for synaptic transmissions, cellular migration, and survival. Recently, we discovered the high prevalence of somatic mutations within one of the ionotropic glutamate receptors, GRIN2A, in malignant melanoma. Functional characterization of a subset of GRIN2A mutants demonstrated a loss of NMDAR complex formation between GRIN1 and GRIN2A, increased anchorage-independent growth in soft agar, and increased migration. Somatic mutation of GRIN2A results in a dominant negative effect inhibiting the tumor-suppressive phenotype of wild-type (WT) GRIN2A in melanoma. Depletion of endogenous GRIN2A in melanoma cells expressing WT GRIN2A resulted in increased proliferation compared with control. In contrast, short-hairpin RNA depletion of GRIN2A in mutant cell lines slightly reduced proliferation. Our data show that somatic mutation of GRIN2A results in increased survival, and we demonstrate the functional importance of GRIN2A mutations in melanoma and the significance that ionotropic glutamate receptor signaling has in malignant melanoma.

Citing Articles

Genetic Backgrounds Associated With Stent Thrombosis: A Pilot Study From a Percutaneous Coronary Intervention Registry.

Shoji S, Sawano M, Inohara T, Hiraide T, Ueda I, Suzuki M JACC Adv. 2024; 2(1):100172.

PMID: 38939036 PMC: 11198226. DOI: 10.1016/j.jacadv.2022.100172.


Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.

Haugh A, Osorio R, Francois R, Tawil M, Tsai K, Tetzlaff M Cancers (Basel). 2024; 16(7).

PMID: 38611025 PMC: 11011039. DOI: 10.3390/cancers16071347.


Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma.

Huang Z, Chen Z, Song E, Yu P, Chen W, Lin H Appl Biochem Biotechnol. 2024; 196(10):6974-6992.

PMID: 38446410 DOI: 10.1007/s12010-024-04894-7.


GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.

Li G, Chang R, Liu T, Jin G, Lu K, Yong T Cancer Gene Ther. 2024; 31(4):586-598.

PMID: 38267623 DOI: 10.1038/s41417-024-00730-6.


The role of glutamate receptors in the regulation of the tumor microenvironment.

Koda S, Hu J, Ju X, Sun G, Shao S, Tang R Front Immunol. 2023; 14:1123841.

PMID: 36817470 PMC: 9929049. DOI: 10.3389/fimmu.2023.1123841.


References
1.
Ru W, Peng Y, Zhong L, Tang S . A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2). J Mol Neurosci. 2012; 47(2):340-5. DOI: 10.1007/s12031-012-9753-1. View

2.
Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M . Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009; 132(4):435-45. DOI: 10.1007/s00418-009-0613-1. View

3.
Hahn C, Wang H, Cho D, Talbot K, Gur R, Berrettini W . Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006; 12(7):824-8. DOI: 10.1038/nm1418. View

4.
Schlett K . Glutamate as a modulator of embryonic and adult neurogenesis. Curr Top Med Chem. 2006; 6(10):949-60. DOI: 10.2174/156802606777323665. View

5.
Ye Z, Sontheimer H . Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999; 59(17):4383-91. View